Stock HEM HEMOSTEMIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Hemostemix Inc.

Equities

HEM

CA4236943060

Delayed Toronto S.E.
Other stock markets
 01:00:27 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.04 CAD -11.11% Intraday chart for Hemostemix Inc. -20.00% -42.86%
Feb. 06 Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences CI
2023 Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
NE
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
CI
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
NE
Hemostemix Clarifies its October 3, 2023 News Release
NE
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease
CI
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
NE
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
NE
Hemostemix Closed Private Placement
MT
Hemostemix Closed $320,125 Private Placement
NE
Hemostemix Inc. announced that it has received CAD 0.320385 million in funding
CI
Hemostemix Inc. announced that it expects to receive CAD 0.325125 million in funding
CI
Hemostemix Announces Private Placement
NE
Hemostemix Inc. announced that it has received CAD 0.72754 million in funding
CI
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication
CI
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
AQ
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
AQ
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal
CI
The Benefits of ACP-01 Stem Cell Therapy: Can it Save Limbs and thereby Lives
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HEM Stock
  4. News Hemostemix Inc.